TB Directly Observed Therapy Criteria (NICE NG33)
NICE NG33 criteria for offering directly observed therapy (DOT) as part of enhanced case management for active TB. In children whose parents meet any criterion, offer DOT too (NICE NG33 1.7.1.4).
Score interpretation
None of the NICE NG33 1.7.1.3 criteria is present.
→ Standard case management: named TB case manager, risk assessment, education and an agreed care plan. Re-evaluate the need for DOT whenever circumstances change (NICE NG33 1.7.1).
At least one NICE NG33 1.7.1.3 criterion is present.
→ Offer DOT as part of enhanced case management, at a convenient location (e.g. a methadone clinic); address social and support needs in the care plan; involve the TB case manager / community TB nurse.
Interpretation bands for the TB DOT Criteria. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Estradiol (HRT — Hormone Replacement Therapy) · Oestrogen Replacement Therapy
- Allopurinol · Xanthine Oxidase Inhibitor — Urate-lowering Therapy
- Febuxostat · Xanthine Oxidase Inhibitor — Urate-lowering Therapy
- Nicotine · Nicotine replacement therapy (NRT)
- Eliglustat · Glucosylceramide synthase inhibitor (substrate reduction therapy)
- Allopurinol · Xanthine Oxidase Inhibitor — Urate-Lowering Therapy
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.